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Abstract
Aim: The modified Rodnan skin score (mRSS) is a validated outcome measure for skin 
thickness in systemic sclerosis (SSc). Training has been shown to reduce variability in 
the measurement of mRSS. Our objective was to assess the inter- and intra-observer 
variability of mRSS scoring using the proposed recommendations for training by the 
Scleroderma Clinical Trials Consortium (SCTC) and World Scleroderma Foundation 
(WSF).
Method: Fifty-two trainees and eight adult SSc patients participated in the SSc skin 
scoring workshop that was conducted in two sessions by four teachers. Each session, 
attended by 26 trainees, had a teaching and evaluation phase. The teaching phase 
comprised of: (a) lecture on mRSS scoring; (b) video demonstration of mRSS scoring; 
and (c) live demonstration of mRSS on one SSc patient. In the evaluation phase, each 
trainee independently assessed the mRSS in four SSc patients. For intra-observer 
reliability, 14 trainees re-assessed the mRSS of two SSc patients whom they had pre-
viously examined. We computed the inter- and intra-observer variability using a lin-
ear mixed model.
Results: For the evaluation phase, 34 (65.4%) trainees were within five units of the 
established teachers’ score in 3 out of 4 patients. Overall, the whole group had ac-
ceptable inter-observer variability (intra-class correlation coefficient [ICC] = 0.71, 
mean = 8.64 and within-patient standard deviation [SD] = 4.25). The intra-observer 
ICC was 0.85 and within-patient SD was 2.73.
Conclusion: There was good inter-observer and excellent intra-observer reliability. 
This is the first study examining the training of assessors using the SCTC/WSF rec-
ommendations and our results support the importance of standardized training for 
skin scoring.
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1  | INTRODUC TION
Systemic sclerosis (SSc) is characterized by skin tightening and thick-
ening. Based on the extent of skin involvement, SSc is sub-classified 
into limited cutaneous SSc (lcSSc) with skin thickening distal to the 
elbows and knees with or without face involvement, or diffuse cuta-
neous SSc (dcSSc) with skin thickening proximal as well as distal to 
the elbows and knees, and can occur with or without involvement 
of the face.1 In particular, early in the disease, more extensive skin 
involvement is associated with more severe internal organ manifes-
tations and poorer prognosis.2,3 The modified Rodnan skin score 
(mRSS)4 is a validated outcome measure for skin thickness in SSc 
clinical trials. It is recommended that the same assessor examine the 
patient for the duration of the trial as each outcome measure in-
herently has measurement variability.5 Training assessors has been 
shown to reduce variability in mRSS assessment.5
The aim of this study was to assess the effectiveness of a sys-
tematic training workshop on standardization of mRSS in SSc as 
per the recommendations proposed by the Scleroderma Clinical 
Trials Consortium (SCTC)/World Scleroderma Foundation (WSF) 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431585/pdf/
nihms849080.pdf).
2  | METHODS
We assessed the inter- and intra-observer variability of mRSS in a group 
of trainees who participated in the skin score workshop conducted 
as part of the 18th Singapore Society of Rheumatology-Malaysian 
Society of Rheumatology pre-congress workshops in Singapore.
2.1 | Participants
Two SSc experts (DK, AL) and two facilitators (GC, NSC), 52 train-
ees and eight adult SSc patients of Asian descent fulfilling the 2013 
American College of Rheumatology/European League Against 
Rheumatism criteria participated in a SSc skin scoring workshop. DK 
is an expert in SSc who co-authored the manuscript on the stand-
ardization of mRSS5 and is a member of the SCTC. AL is a local SSc 
expert with more than 500 SSc patient visits per year, a member of 
the SCTC, and has been trained and facilitated in two prior SSc work-
shops in Singapore by Dr D. Furst (2009) and Dr C. Denton (2014). 
The two facilitators are rheumatologists who have participated in the 
Singapore Scleroderma Research Workgroup since 2009 and they 
assisted with the conduct of the workshop. The 52 trainees included 
physicians and research coordinators. Of the eight SSc patients, four 
had lcSSc and four had dcSSc (see Table 1 for their mRSS scores).
2.2 | Skin scoring
The mRSS is calculated by summation of measurements of skin thick-
ness in 17 different body sites including the face, upper arms, fore-
arms, dorsum of hands, fingers, chest, abdomen, thighs, legs and feet. 
The maximum total score is 51 and each area is graded as follows: 
0 = normal skin, 1 = mild skin thickening, 2 = moderate skin thicken-
ing with difficulty in making skin folds and no wrinkles, 3 = severe 
skin thickness with inability to make skin folds between two exam-
ining fingers.5 Trainees were taught that the three commonly used 
techniques for mRSS skin scoring are that of global average, maxi-
mum score and representative area. For purposes of standardization 
in this workshop, the global average method was used.
2.3 | Conduct of the skin scoring workshop
Similar to how other workshops are conducted,6 the experts first 
evaluated the eight patients together with the facilitators to establish 
the standard teachers’ mRSS score. The workshop was conducted in 
two sessions, with each session comprising of a teaching phase and 
an evaluation phase (Figure 1). The duration of each session was ap-
proximately 2 hours and included 26 trainees per session.
The teaching phase comprised of a: (a) lecture on mRSS skin scoring 
by an SSc expert (DK); (b) video demonstration of mRSS skin scoring 
by Dr D. Furst, an SSc expert, examining a patient exhibiting different 
aspects of skin thickness that corresponds to the expected values of 
the mRSS using the global average method; and (c) live demonstration 
of mRSS scoring on one of the eight SSc patients by DK or AL.
For the evaluation phase, the trainees were divided into two groups 
(Groups A and B), with each group evaluating four patients. Trainees 
were given a mRSS sheet as per the SCTC/WSF recommendations and 
approximately 5 minutes to evaluate one patient. Discussion was not 
allowed during the evaluation. Feedback was provided to the trainees 
at the end of the session. The mRSS scoring for each trainee was then 
compared to the established teachers’ mRSS score: a score difference 
of ≤5 in 3 out of 4 subjects scored by the trainee was considered ac-
ceptable inter-observer variability.5 Trainees who achieved this passed 
the evaluation phase of the workshop and obtained mRSS scoring cer-
tification for the conduct of clinical trials.
To assess intra-observer variability, 14 randomly selected train-
ees and two experts re-assessed the mRSS of the same SSc patients 
TA B L E  1   Modified Rodnan skin scores (mRSS) of 8 systemic 
sclerosis patients
mRSS
Mean (SD) mRSS 
in each group
Group A
Patient 1 14
Patient 2 0 6 (5.9)
Patient 3 4
Patient 4 6
Group B
Patient 5 3
Patient 6 6 5 (4.7)
Patient 7 11
Patient 8 0
1038  |     LOW et aL.
(two each for trainees and four each for experts) whom they had 
examined 2 days ago. The repeat mRSS score for each trainee was 
compared to their original scores. A score of ≤3 was considered ac-
ceptable intra-observer variability, as supported by previous studies 
with an intra-observer variability of 2.5-2.9.6
2.4 | Statistical analysis
We computed the inter- and intra-observer variability using a lin-
ear mixed model with an intercept term, a random effect for the 
patient, a random effect for the scorer, and a random effect for 
the interaction of patient and scorer, as previously described.7 
Inter-observer variability was calculated for the 52 trainees in the 
evaluation phase and intra-observer variability was calculated for 
the 14 trainees and two experts who returned 2 days later for 
repeat scoring. Agreement among scorers was quantified via the 
intra-class correlation coefficient (ICC). Usual interpretations of 
the ICC are as follows: values of 0.4-0.6 are considered moder-
ate; 0.6-0.8 are deemed good and 0.8-1.0 are considered excel-
lent agreement. Summary statistics (mean and within-patient 
standard deviation, SD) were calculated for the skin scores along 
with the coefficient of variation (SD/mean). Statistical analysis 
was performed using the R statistical software, version 3.4.2 (R 
Foundation, Vienna, Austria). This study was approved by the 
Singhealth Centralised Institutional Review Board, with waiver of 
consent obtained.
3  | RESULTS
Participants of the workshop came from five different Asian coun-
tries (Singapore, Malaysia, Indonesia, Myanmar, Qatar), and were 
rheumatologists, rheumatology trainees, research coordinators and 
dermatologists.
For the evaluation phase, 34 of 52 trainees (65.4%) achieved ac-
ceptable inter-observer variability and were within five units of the 
established teachers’ score (median [range] mRSS 5 [0-14] by teach-
ers vs 8.6 [0-34] by trainees). The inter-observer variability ICC was 
0.71 and the within-patient SD was 4.25 units. The two experts (DK/
AL) were within two units in mRSS scores for each of the eight SSc 
patients.
The intra-observer variability for the 14 trainees and two ex-
perts 2 days later showed an acceptable within-patient SD of 2.56 
(see Table 2). The test-retest score was within one unit for the ex-
perts. The coefficient of variation was 39%.
4  | DISCUSSION
The mRSS is a feasible, reliable, valid, and responsive measure and 
is used as a primary or secondary outcome measure in clinical tri-
als.8 In a Phase 2 trial,9 mRSS was able to differentiate tocilizumab 
from placebo. Mycophenolate mofetil and cyclophosphamide were 
both shown to be superior to placebo in post-hoc analysis of the 
F I G U R E  1   Flow diagram summarizing the conduct of skin score workshop. mRSS, modified Rodnan skin score; SSc, systemic sclerosis
Establishment 
of intra-
observer 
reliability
Teaching 
Phase
Evaluaon 
Phase
Lecture on mRSS scoring
Video demonstraon of mRSS scoring
Live demonstraon of mRSS scoring on a paent
Each trainee performs mRSS scoring on 4 SSc paents using 
standardized mRSS sheet
Feedback given to trainees
Session 1  
(2 hours; 
n = 26)
14 randomly selected trainees and 2 experts re-evaluate 
the same paents they had scored earlier
2 days later
Repeat for Session 2 (another n = 26)
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Scleroderma Lung Study I and II10 using mRSS as the primary out-
come measure. It is important that in the modern era of SSc clinical 
trials, outcome measures should be valid, reliable and responsive to 
change.11 With new insights on the pathogenesis of SSc, there are 
several targeted novel therapies that are being assessed for skin and 
interstitial lung disease. Due to the orphan nature of the disease, 
the trials are being conducted in different countries to recruit ap-
propriate patients. Multi-center recruitment across different regions 
provides more robust and generalizable results as it accounts for 
variability in different regions, such as the well-recognized differ-
ences in autoantibodies and severity of skin thickness by regions. 
However, this may result in higher inter-observer variability in the 
primary outcome measure, the mRSS. One way to reduce this vari-
ability is to protocolize the way patients are evaluated to reduce 
variability between assessors due to subtle differences in assessing 
the mRSS and also different methods utilized in scoring mRSS (global 
average vs maximum score vs representative area). The global aver-
age and representative area techniques are recommended as they 
are likely more sensitive to change than the maximum score tech-
nique.5 The intra-observer variability has been shown consistently 
by various studies to be lower than inter-observer variability.6,7,12 It 
is therefore recommended that the same assessor evaluates the pa-
tient throughout a trial to reduce measurement variability. Training of 
practitioners in mRSS evaluation will have the effect of reducing the 
variability and provides a platform to standardize mRSS for a trial.5 
Although the teaching and standardization has been performed in 
different trials (Dr D.K. Khanna, personal communication), to our 
knowledge, this is the first study to prospectively incorporate the 
SCTC/WSF recommendations in a group of general rheumatologists 
and research coordinators. We determined that training workshops 
are feasible, and we found good inter-observer reliability and excel-
lent intra-observer reliability for mRSS scoring in a group of trainees 
who underwent a structured and standardized mRSS workshop. This 
study is an important contribution to the field as it provides evidence 
of intra-rater and inter-rater reliability among both physicians and 
research staff.
The inter-observer SD was noticed to be 4.3 units and was con-
sistent with previous studies6 (within-patient SD 3.8-8.5), and was 
well within the recommended SCTC/WSF proposed upper limit of 
five units. Likewise, the intra-observer within-patient SD was con-
sistent with previously reported figures of 2.5-2.9.
Few studies have been conducted to investigate intra-observer 
variability of mRSS scoring. We report intra-observer variability on 
the same group of patients examined 2 days after the initial train-
ing session. This would have reduced recall bias compared to the 
study by Gordon et al, where patients were re-examined on the 
same day with an intra-observer variability of 0.94.7 In the studies 
by Clements et al12 and Czirjak et al6 patients were re-examined 
2-8 weeks later to quantitate intra-observer variability and the intra-
observer within-patient SD was found to be 2.5-2.9.
The coefficient of variation (CV) was on the higher end of the range 
in our study (39%-56%) compared to other studies (11.8%-54%)6,7,12 
despite acceptable within-patient SD for both inter- and intra-ob-
server variability. This could be due to the lower median skin score 
of five in our patients compared to mean scores of 8.6-20.7 reported 
in other studies, resulting in a larger CV for minimal variation in SD 
(since CV is derived from SD divided by the mean).
The lower ICC when experts were included in the analysis for 
intra-observer variability likely reflected the tendency for most 
trainees to score higher than the experts, an observation similarly 
noted in other studies,6 where skin tethering may erroneously be 
scored as skin thickness.
Our data shows that 65.4% of the trainees were provided certifi-
cates, based on the predefined variability of up to five units. We do not 
have published data from other studies on proportion of those who 
passed the evaluation phase but this is likely lower due to the mix of 
the trainees. In the opinion of the senior author (DK), the proportion 
is higher in those who perform skin scoring training on a regular basis 
in clinics or those who have participated in previous clinical trials. To 
address over-scoring of skin tethering, training workshops can include 
patients with higher mRSS scores (ie reflective of how patients are en-
riched for clinical trials) as well as patients with atrophic and tethered 
skin so as to emphasize their difference, to further improve training.
We believe our results are especially encouraging as the train-
ees were of a heterogeneous background ranging from experienced 
rheumatologists to rheumatology trainees to research coordinators 
with no medical training, many of whom are not scleroderma ex-
perts. Further, the findings from our study may be generalized to 
TA B L E  2   Inter-and intra-observer variability for skin score workshop
Evaluation phase No. of subjects
Inter‐observer variability
Mean Within‐patient SD
Coefficient of 
variation %
Intra‐class correlation 
coefficient
Trainees (n = 52) 4 8.64 4.25 49 0.71
Establishment of 
intra‐observer 
reliability No. of subjects
Intra‐observer variability
Mean Within‐patient SD
Coefficient of 
variation %
Intra‐class correlation 
coefficient
Trainees (n = 14) and 
experts (n = 2)
2 6.56 2.56 39 0.86
Trainees only (n = 14) 2 6.92 2.73 39 0.85
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patients of Asian descent. Previous studies demonstrated no signif-
icant differences in initial or peak mRSS between SSc patients of 
Asian descent and their European counterparts.13,14
Our study has several limitations. Ideally the repeat scoring to 
evaluate intra-observer variability could have been done 2-4 weeks 
later to further minimize recall bias which may occur within a 2-day 
interval. This has to be balanced against a longer interval (eg more 
than 3 months) when any change in skin scores may be due to disease 
improvement or worsening. The mean skin scores of patients who 
participated in the workshop were lower than other studies with a 
range of mRSS from 0 to 14. This limitation could be addressed in 
future training workshops conducted in Asian patients by including 
patients with higher mRSS scores. Pre-workshop assessment of the 
trainees could also have been conducted so as to compare trainees’ 
performances pre- and post-workshop to further support the SCTC/
WSF training recommendations.
In summary, this is the first study examining the training of asses-
sors using the SCTC/WSF training recommendations demonstrating 
good and excellent inter- and intra-observer variability for skin scor-
ing. Standardized training of skin scoring is strongly encouraged to 
enable reliable mRSS scoring, a key outcome measure in SSc clinical 
trials.
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